BRIEF published on 11/04/2024 at 11:51, 1 year 1 month ago Acticor Biotech : Publication des résultats financiers semestriels 2024 Résultats Semestriels Biotechnologie Finance Redressement Judiciaire Glenzocimab
BRIEF published on 11/04/2024 at 11:51, 1 year 1 month ago Acticor Biotech: Publication of 2024 half-year financial results Biotechnology Finance Half-year Results Glenzocimab Judicial Recovery
PRESS RELEASE published on 11/04/2024 at 11:46, 1 year 1 month ago Informations privilégiées / Communiqué sur comptes, résultats Acticor Biotech publie ses résultats financiers semestriels 2024 et annonce le repositionnement du glenzocimab dans le traitement de l’infarctus du myocarde avec élévation du segment ST (STEMI) Résultats Financiers ACTICOR BIOTECH Glenzocimab Repositionnement Infarctus Du Myocarde
PRESS RELEASE published on 11/04/2024 at 11:46, 1 year 1 month ago Inside Information / News release on accounts, results Acticor Biotech publishes its half-year financial results for 2024, highlighting repositioning of glenzocimab in STEMI treatment, receivership proceedings extension, and shareholder approvals Repositioning Shareholder Approvals ACTICOR BIOTECH Glenzocimab Half-year Financial Results
BRIEF published on 10/11/2024 at 17:50, 1 year 2 months ago Acticor Biotech Advances Glenzocimab in Myocardial Infarction Treatment Clinical Trials Myocardial Infarction ACTICOR BIOTECH Glenzocimab Cardiovascular Treatment
BRIEF published on 10/11/2024 at 17:50, 1 year 2 months ago Acticor Biotech fait progresser le Glenzocimab dans le traitement de l'infarctus du myocarde Essais Cliniques ACTICOR BIOTECH Glenzocimab Infarctus Du Myocarde Traitement Cardiovasculaire
PRESS RELEASE published on 10/11/2024 at 17:45, 1 year 2 months ago Inside Information / Other news releases Acticor Biotech repositions glenzocimab in the treatment of myocardial infarction, evaluating efficacy and safety in phase 2 studies LIBERATE and GLORIA. Clinical trials aim to reduce infarct size and prevent complications Clinical Trials Phase 2b Myocardial Infarction ACTICOR BIOTECH Glenzocimab
PRESS RELEASE published on 10/11/2024 at 17:45, 1 year 2 months ago Informations privilégiées / Autres communiqués Repositionnement de glenzocimab dans le traitement de l'infarctus du myocarde par Acticor Biotech. Nouvelle étude de phase 2b LIBERATE et préparation de l'étude GLORIA Traitement Étude Clinique ACTICOR BIOTECH Glenzocimab Infarctus Du Myocarde
BRIEF published on 07/09/2024 at 20:50, 1 year 5 months ago Acticor Biotech Reports 2023 Financial Results Financial Report Annual Results Capital Raising ACTICOR BIOTECH Glenzocimab
BRIEF published on 07/09/2024 at 20:50, 1 year 5 months ago Acticor Biotech publie ses résultats financiers pour 2023 Résultats Annuels Rapport Financier ACTICOR BIOTECH Glenzocimab Levée De Capitaux
Published on 12/19/2025 at 00:00, 39 minutes ago LIR Life Sciences Announces Appointment of Dr. Peter Singer as Scientific Advisor
Published on 12/18/2025 at 23:10, 1 hour 29 minutes ago Air T, Inc. Announces Closing of Regional Express Acquisition
Published on 12/18/2025 at 23:05, 1 hour 34 minutes ago BlackBerry Reports Third Quarter Fiscal Year 2026 Results
Published on 12/18/2025 at 22:45, 1 hour 54 minutes ago Stabilis Solutions Announces Multi-Year Marine Bunkering Agreement with Carnival Coprporation at Proposed Galveston LNG Liquefaction Facility
Published on 12/18/2025 at 22:05, 2 hours 34 minutes ago Abivax fait son entrée au sein de l'indice Nasdaq Biotechnology
Published on 12/18/2025 at 22:05, 2 hours 34 minutes ago Abivax to be Added to Nasdaq Biotechnology Index
Published on 12/18/2025 at 20:09, 4 hours 29 minutes ago EQS-Adhoc: The Grounds Real Estate Development AG: Conversion of the EUR 17 million bond issued in 2023/2024 into a hybrid bond
Published on 12/18/2025 at 19:30, 5 hours 9 minutes ago Prodware: COMMUNIQUE DU 18 DECEMBRE 2025 RELATIF A LA MISE A DISPOSITION DE LA NOTE EN REPONSE ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES DANS LE CADRE DE L’OFFRE PUBLIQUE DE RETRAIT
Published on 12/18/2025 at 19:30, 5 hours 9 minutes ago Prodware: COMMUNIQUE DU 18 DECEMBRE 2025 RELATIF A LA MISE A DISPOSITION DE LA NOTE D’INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES , NOTAMMENT JURIDIQUES, FINANCIERE DE PHAST INVEST
Published on 12/18/2025 at 18:30, 6 hours 9 minutes ago Schneider Electric completes transaction to acquire remaining 35% stake in existing Indian JV
Published on 12/18/2025 at 18:30, 6 hours 9 minutes ago Schneider Electric finalise l’opération d’acquisition des 35% restants du capital de sa JV existante en Inde
Published on 12/18/2025 at 17:45, 6 hours 54 minutes ago Cie du Bois Sauvage: Vernietiging eigen aandelen
Published on 12/18/2025 at 17:45, 6 hours 54 minutes ago Damartex réaffirme son éligibilité au PEA-PME
Published on 12/18/2025 at 17:45, 6 hours 54 minutes ago Cie du Bois Sauvage : Cancellation of own shares
